» Articles » PMID: 29264548

Activation of Sphingolipid Pathway in the Livers of Lipodystrophic Mice

Overview
Journal J Endocr Soc
Specialty Endocrinology
Date 2017 Dec 22
PMID 29264548
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

A several fold increase in triacylglycerol is observed in the livers of lipodystrophic mice. We have previously reported an unexpected increase in the phosphatidic acid (PA) levels in the livers of these mice and that a few specific molecular species of PA were able to transcriptionally upregulate hepatic gluconeogenesis. In the current study, we measured the metabolites and expression of associated enzymes of the sphingolipid synthesis pathway. The entire sphingolipid pathway was activated both at the gene expression and the metabolite level. The levels of some ceramides were increased by as much as ~eightfold in the livers of mice. Furthermore, several molecular species of ceramides were increased in the plasma of mice, specifically ceramide C16:0, which was threefold elevated in the plasma of both the sexes. However, the ceramides failed to increase glucose production in mouse primary hepatocytes obtained from wild-type and mice, further establishing the specificity of PA in the induction of hepatic gluconeogenesis. This study shows elevated levels of sphingolipids in the steatotic livers of mice and increased expression of associated enzymes for the sphingolipid pathway. Therefore, this study and those in the literature suggest that ceramide C16:0 could be used as a biomarker for insulin resistance/type 2 diabetes mellitus.

Citing Articles

Regulated regeneration of adipose tissue in lipodystrophic -null mice partially ameliorates hepatic steatosis.

Agarwal A, Tunison K, Horton J, Garg A iScience. 2024; 27(4):109517.

PMID: 38623324 PMC: 11016861. DOI: 10.1016/j.isci.2024.109517.


Adipose-specific overexpression of human AGPAT2 in mice causes increased adiposity and mild hepatic dysfunction.

Agarwal A, Tunison K, Vale G, McDonald J, Li X, Horton J iScience. 2024; 27(1):108653.

PMID: 38274405 PMC: 10809107. DOI: 10.1016/j.isci.2023.108653.


Roles of Ceramides in Non-Alcoholic Fatty Liver Disease.

Hajduch E, Lachkar F, Ferre P, Foufelle F J Clin Med. 2021; 10(4).

PMID: 33669443 PMC: 7920467. DOI: 10.3390/jcm10040792.


Sphingolipids in Obesity and Correlated Co-Morbidities: The Contribution of Gender, Age and Environment.

Torretta E, Barbacini P, Al-Daghri N, Gelfi C Int J Mol Sci. 2019; 20(23).

PMID: 31771303 PMC: 6929069. DOI: 10.3390/ijms20235901.


Insights into lipid accumulation in skeletal muscle in dysferlin-deficient mice.

Agarwal A, Tunison K, Mitsche M, McDonald J, Garg A J Lipid Res. 2019; 60(12):2057-2073.

PMID: 31653658 PMC: 6889719. DOI: 10.1194/jlr.RA119000399.

References
1.
Turpin S, Nicholls H, Willmes D, Mourier A, Brodesser S, Wunderlich C . Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 2014; 20(4):678-86. DOI: 10.1016/j.cmet.2014.08.002. View

2.
Pulkoski-Gross M, Donaldson J, Obeid L . Sphingosine-1-phosphate metabolism: A structural perspective. Crit Rev Biochem Mol Biol. 2015; 50(4):298-313. PMC: 5476942. DOI: 10.3109/10409238.2015.1039115. View

3.
Harayama T, Shindou H, Ogasawara R, Suwabe A, Shimizu T . Identification of a novel noninflammatory biosynthetic pathway of platelet-activating factor. J Biol Chem. 2008; 283(17):11097-106. DOI: 10.1074/jbc.M708909200. View

4.
Merrill Jr A . De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J Biol Chem. 2002; 277(29):25843-6. DOI: 10.1074/jbc.R200009200. View

5.
Brozinick J, Hawkins E, Hoang Bui H, Kuo M, Tan B, Kievit P . Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet. Int J Obes (Lond). 2012; 37(8):1064-70. PMC: 3718866. DOI: 10.1038/ijo.2012.191. View